Grey Wilkinson

762 total citations
21 papers, 520 citations indexed

About

Grey Wilkinson is a scholar working on Biotechnology, Genetics and Molecular Biology. According to data from OpenAlex, Grey Wilkinson has authored 21 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Biotechnology, 10 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Grey Wilkinson's work include Cancer Research and Treatments (12 papers), Virus-based gene therapy research (9 papers) and Neurogenesis and neuroplasticity mechanisms (6 papers). Grey Wilkinson is often cited by papers focused on Cancer Research and Treatments (12 papers), Virus-based gene therapy research (9 papers) and Neurogenesis and neuroplasticity mechanisms (6 papers). Grey Wilkinson collaborates with scholars based in United States, Canada and Germany. Grey Wilkinson's co-authors include Carol Schuurmans, Daniel J. Dennis, Deborah M. Kurrasch, Rajiv Dixit, Saiqun Li, Pierre Mattar, Jennifer A. Chan, Patrick Raber, Kevin H. Eng and Paul Fields and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Grey Wilkinson

21 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Grey Wilkinson United States 8 319 149 144 133 59 21 520
Olga Machoňová Czechia 10 653 2.0× 94 0.6× 138 1.0× 105 0.8× 89 1.5× 14 849
Abhijeet Pataskar Germany 12 500 1.6× 117 0.8× 64 0.4× 50 0.4× 72 1.2× 18 644
Ariadna Perez‐Balaguer Spain 12 498 1.6× 54 0.4× 73 0.5× 56 0.4× 53 0.9× 14 607
Greger Abrahamsen Norway 10 250 0.8× 61 0.4× 82 0.6× 55 0.4× 86 1.5× 15 551
Daniela Cornacchia United States 11 872 2.7× 87 0.6× 67 0.5× 86 0.6× 99 1.7× 13 969
Erik Runko United States 11 261 0.8× 115 0.8× 89 0.6× 38 0.3× 240 4.1× 13 484
Raffaella Catena France 8 790 2.5× 168 1.1× 66 0.5× 236 1.8× 63 1.1× 8 986
Francesca Cavallo United States 12 416 1.3× 36 0.2× 157 1.1× 46 0.3× 53 0.9× 15 560
Nazario Bosco United States 8 595 1.9× 24 0.2× 61 0.4× 171 1.3× 40 0.7× 10 756
Denise E. Allen United States 6 443 1.4× 155 1.0× 28 0.2× 59 0.4× 81 1.4× 6 601

Countries citing papers authored by Grey Wilkinson

Since Specialization
Citations

This map shows the geographic impact of Grey Wilkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grey Wilkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grey Wilkinson more than expected).

Fields of papers citing papers by Grey Wilkinson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grey Wilkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grey Wilkinson. The network helps show where Grey Wilkinson may publish in the future.

Co-authorship network of co-authors of Grey Wilkinson

This figure shows the co-authorship network connecting the top 25 collaborators of Grey Wilkinson. A scholar is included among the top collaborators of Grey Wilkinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grey Wilkinson. Grey Wilkinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Daneng, et al.. (2024). Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2687–TPS2687. 2 indexed citations
2.
Li, Daneng, Anthony F. Shields, Hirva Mamdani, et al.. (2024). Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.. Journal of Clinical Oncology. 42(3_suppl). 749–749. 1 indexed citations
3.
4.
Williams, Nicole, Coral Omene, Shou‐En Lu, et al.. (2022). Abstract OT2-25-01: Irene study: Phase 2 study of Incmga00012 and the oncolytic virus pelareorep in metastatic triple negative breast cancer. Cancer Research. 82(4_Supplement). OT2–25. 1 indexed citations
5.
Mahalingam, Devalingam, Siqi Chen, Ping Xie, et al.. (2021). Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology. 39(15_suppl). 4144–4144. 3 indexed citations
6.
Williams, Nicole, Maryam B. Lustberg, Coral Omene, et al.. (2021). Abstract OT-32-02: Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer. Cancer Research. 81(4_Supplement). OT–32. 3 indexed citations
7.
8.
Manso, Luís, Patricia Villagrasa, Núria Chic, et al.. (2020). 41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1). Annals of Oncology. 31. S30–S30. 2 indexed citations
9.
Mahalingam, Devalingam, Aparna Kalyan, Sheetal Kircher, et al.. (2020). Pembrolizumab in combination with the oncolytic virus pelareorep in patients progressing on systemic chemotherapy for advanced pancreatic adenocarcinoma: A phase II study.. Journal of Clinical Oncology. 38(15_suppl). e16789–e16789. 1 indexed citations
10.
11.
Mahalingam, Devalingam, Grey Wilkinson, Kevin H. Eng, et al.. (2019). Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clinical Cancer Research. 26(1). 71–81. 142 indexed citations
12.
Fountzilas, Christos, Grey Wilkinson, Kevin H. Eng, et al.. (2019). Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 37(15_suppl). e15726–e15726. 2 indexed citations
13.
Dennis, Daniel J., Grey Wilkinson, Saiqun Li, et al.. (2017). Neurog2 and Ascl1 together regulate a postmitotic derepression circuit to govern laminar fate specification in the murine neocortex. Proceedings of the National Academy of Sciences. 114(25). E4934–E4943. 29 indexed citations
14.
Rosin, Jessica M., et al.. (2016). Oligodendrocyte development in the embryonic tuberal hypothalamus and the influence of Ascl1. Neural Development. 11(1). 20–20. 27 indexed citations
15.
Adnani, Lata, Lisa Marie Langevin, Élodie Gautier, et al.. (2015). Zac1Regulates the Differentiation and Migration of Neocortical Neurons viaPac1. Journal of Neuroscience. 35(39). 13430–13447. 25 indexed citations
16.
Li, Saiqun, Pierre Mattar, Rajiv Dixit, et al.. (2014). RAS/ERK Signaling Controls Proneural Genetic Programs in Cortical Development and Gliomagenesis. Journal of Neuroscience. 34(6). 2169–2190. 86 indexed citations
17.
Dixit, Rajiv, Grey Wilkinson, Gonzalo I. Cancino, et al.. (2014). Neurog1andNeurog2Control Two Waves of Neuronal Differentiation in the Piriform Cortex. Journal of Neuroscience. 34(2). 539–553. 49 indexed citations
18.
Wilkinson, Grey, Daniel J. Dennis, & Carol Schuurmans. (2013). Proneural genes in neocortical development. Neuroscience. 253. 256–273. 97 indexed citations
19.
Kovach, Christopher P., Rajiv Dixit, Saiqun Li, et al.. (2012). Neurog2 Simultaneously Activates and Represses Alternative Gene Expression Programs in the Developing Neocortex. Cerebral Cortex. 23(8). 1884–1900. 41 indexed citations
20.
Banman, Shanna L., et al.. (2011). TCERG1 inhibits C/EBPα through a mechanism that does not involve sequestration of C/EBPα at pericentromeric heterochromatin. Journal of Cellular Biochemistry. 112(9). 2317–2326. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olga Machoňová Breakdown of academic impact, for papers by Abhijeet Pataskar Breakdown of academic impact, for papers by Ariadna Perez‐Balaguer Breakdown of academic impact, for papers by Greger Abrahamsen Breakdown of academic impact, for papers by Daniela Cornacchia Breakdown of academic impact, for papers by Erik Runko Breakdown of academic impact, for papers by Raffaella Catena Breakdown of academic impact, for papers by Francesca Cavallo Breakdown of academic impact, for papers by Nazario Bosco Breakdown of academic impact, for papers by Denise E. Allen
Rankless by CCL
2026